Will breakfast change how this diabetes drug works?

NCT ID NCT07396844

Not yet recruiting Knowledge-focused Sponsor: LG Chem Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial in 28 healthy adults tests whether eating a meal changes how the body absorbs a single tablet containing three diabetes medicines (gemigliptin, dapagliflozin, and metformin). Participants take the pill once while fasting and once after a meal, and researchers measure drug levels in the blood. The goal is to understand food effects, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemigliptin/Dapagliflozin/Metformin fixed-dose combination tablet
What this could lead to: If successful, this study could show that taking this combination diabetes pill with or without food is safe and absorbed similarly, guiding future dosing instructions.
What could go wrong: This is a very early Phase 1 study in only 28 healthy people, not patients. It only measures drug levels, not effectiveness or long-term safety. Results may not apply to people with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FASTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fasting fish eye disease Lecithin Cholesterol Acyltransferase Deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FASTING FED HEALTHY

Contacts and locations

Locations

Siriraj Hospital

Nakhon Pathom, 73170, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.